Awareness of physicians and pharmacists of aldosterone antagonists in heart failure and myocardial infarction in Jordan

Mayyas, Fadia; Ibrahim, Khalid S.; Alzoubi, Karem H.

doi:10.18549/pharmpract.2017.03.994

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study also showed the need for ongoing team awareness regarding the most common mistakes and new recommendations. This finding of poor knowledge, especially in case of the use of aldosterone antagonist, was reported in a previous study by Mayyas et al 22 It was observed that less than 40.0% of the interviewed physicians and pharmacists were aware of the recommendations for the use of aldosterone antagonists in HF management.…”

Section: Discussionsupporting

confidence: 54%

Collaboration between cardiologist and clinical pharmacist on prescription quality: What is the potential clinical impact for cardiology patients?

et al. 2020

View full text Add to dashboard Cite

Objectives The aim of this study was to determine the effect of pharmacists’ interventions (PI) on the potential clinical impact of medication errors, including the lack of therapeutic optimisation of patients with cardiologic diseases, such as heart failure and acute coronary syndrome). Methods This was an observational, prospective study conducted in the cardiology department of a French university hospital centre for a duration of 9 months. All prescriptions were analysed and PI were registered for clinical rating by pharmacists and cardiologist. Results A total of 532 PI cases were recorded in 339 patients, with a mean of 1.57 (±1.04) PI. The PI acceptance rate was 98.1%. “Dose adjustment” and “introduction therapy” were the most common interventions and represented 38.0% and 32.9%, respectively, of all PI. Statins were the most frequently involved drugs (18.1%), followed by ACE (Angiotensin Converting Enzyme) inhibitors (10.9%) and antiplatelet agents (9.3%). Moreover, 13.8% of PI potentially avoided a severe or very severe clinical impact (n = 71) and 38.6% had a significant impact altering the quality of life (n = 198). There was no significant difference between the average score performed by the clinical pharmacist included in the cardiology team and the one obtained by the cardiologist (P = .797). In contrast, a significant difference was observed for the average score established by the pharmacist localised in central pharmacy versus the rating of the cardiologist (P < .001). Conclusions The collaboration between clinical pharmacists and cardiologists in the medical units seems to be beneficial to the quality of prescriptions, including the implementation of recommendations. The good rate of PI acceptance and the similar rating with the cardiologist show that there is a change in perspective of the pharmacist, being closer to the clinical reality.

show abstract

Section: Discussionsupporting

confidence: 54%

Collaboration between cardiologist and clinical pharmacist on prescription quality: What is the potential clinical impact for cardiology patients?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, international reports suggest that prescribers do not optimally adhere to the recommended HF guideline-led prescribing at discharge from certain clinical settings [2,4]. In one study, more than one-third of eligible HF patients was not prescribed the full list of the recommended HF disease-modifying therapies at discharge [2] Many physicians report poor awareness of the recommendations of the guidelines [5,6]. A national survey in the UK showed that 27% of cardiologists do not use the HF guidelines in managing the disease [7].…”

Section: Introductionmentioning

confidence: 99%

Factors influencing prescribing by critical care physicians to heart failure patients in Egypt: a cross-sectional survey

et al. 2022

View full text Add to dashboard Cite

Background Heart failure (HF) guideline-led prescribing improves patient outcomes; however, little is known about the factors influencing guideline-led prescribing in critical care settings. This study used a cross-sectional survey to assess the factors that influence physicians when prescribing to heart failure patients in a critical care setting in Egypt. Results The response rate was 54.8%. The international HF guidelines were the primary source of prescribing information for 84.2% of respondents. Staff were more familiar with the latest guideline recommendations than associate staff (86.7% vs 36.8%, p = 0.012) and considered patient’s perspectives more often (86.7% vs 26.3%, p = 0.036). Renal function was the clinical factor that most frequently influenced the prescribing of loop diuretics or renin–angiotensin–aldosterone system inhibitors. Pulmonary function influenced beta-blockers prescription. The most frequently cited barrier to guideline-led prescribing was the absence of locally drafted guidelines. A majority of prescribers agreed that implementation of clinical pharmacy services, physician education and electronic reminders may improve the implementation of guideline-led prescribing. Conclusions Although experienced physicians are familiar with and use international guidelines, physicians would welcome local guidance on HF prescribing and greater clinical pharmacist input.

show abstract

Physician Perceptions of Medication Prescribing in Heart Failure: A Scoping Review

Vasudevan,

Thayaparan,

Teng

et al. 2024

Cardiology

View full text Add to dashboard Cite

Introduction: The swift uptake of new medications into clinical practice has many benefits, however slow uptake has been seen previously with other guideline-directed medical therapies (GDMT) in heart failure (HF). Sodium glucose co-transporter 2 inhibitors are a novel therapy in HF proven to be efficacious and will have beneficial clinical outcomes if prescribed. Understanding physician perspectives on prescribing GDMT in HF can help target strategies to bridge the gap between guidelines and practice. Methods: The study followed the PRISMA guide for scoping reviews and the JBI Manual for scoping reviews. A search was conducted using EMBASE, Medline and PubMed databases in April 2024. Studies included were those using qualitative methods to assess physician perspectives towards prescribing any HF medication. Common themes were identified through thematic synthesis following the methods from Cochrane Training and using software MAXQDA Analysis Pro. Results: 708 studies were found in the search, with 23 full studies included. The most pertinent barriers identified were concern for medication adverse effects, unclear role responsibilities between physicians of different specialties, patient comorbidities and unwillingness to alter therapies of stable patients. The most identified enablers included awareness of efficacy, influence from colleagues and the use of multi-media approaches for information dissemination. Perceptions were also found to change over time and vary among prescriber groups. Conclusions: Physicians perceive common barriers and enablers of prescribing GDMT in HF, despite differences in prescriber groups and time periods. The identified barriers and enablers may be targeted to improve implementation of GDMT into clinical practice.

show abstract

Awareness of physicians and pharmacists of aldosterone antagonists in heart failure and myocardial infarction in Jordan

Cited by 3 publications

References 13 publications

Collaboration between cardiologist and clinical pharmacist on prescription quality: What is the potential clinical impact for cardiology patients?

Collaboration between cardiologist and clinical pharmacist on prescription quality: What is the potential clinical impact for cardiology patients?

Factors influencing prescribing by critical care physicians to heart failure patients in Egypt: a cross-sectional survey

Physician Perceptions of Medication Prescribing in Heart Failure: A Scoping Review

Contact Info

Product

Resources

About